Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate)

The allergen extract contains standardized proteins from several grass species. When taken regularly under the tongue, it promotes the development of regulatory T‑cells and allergen‑specific IgG4 antibodies, shifting the immune response away from an IgE‑driven allergic pathway and thereby decreasing the severity of allergic reactions upon natural pollen exposure.

The dosing regimen for Oralair is individualized by the prescribing clinician based on the patient’s age, severity of allergy, and response to therapy. The prescriber determines the starting dose, titration schedule, and maintenance dose, which are typically administered once daily under the tongue during the pre‑seasonal period.

Safety data for Oralair in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should discuss individual circumstances and consider alternative management strategies when appropriate.

To request Oralair, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Oralair is a sublingual tablet that offers a non‑injectable route compared with traditional subcutaneous allergy shots. It provides a convenient at‑home administration schedule and has a favorable safety profile for most patients, though both modalities aim to achieve long‑term immune tolerance. Choice depends on patient preference, medical history and physician recommendation.

Oralair tablets should be stored at ambient temperature below 25 °C, in the original packaging to protect from moisture and direct sunlight. Do not refrigerate or freeze the product. Keep the tablets out of reach of children and avoid exposing them to extreme temperatures.

Oralair is taken as a single tablet placed under the tongue, where it is allowed to dissolve completely without swallowing. Patients should remain upright for at least 30 minutes after dosing and avoid eating or drinking during that time to ensure optimal absorption of the allergen extract.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe bronchospasm, or laryngeal edema. These events are rare but require immediate medical attention. Patients should be educated on recognizing early signs of a severe reaction and have access to emergency medication, such as epinephrine, if prescribed.

Oralair is contraindicated in individuals with a history of severe uncontrolled asthma, previous anaphylactic reaction to grass pollen extracts, or those receiving beta‑blocker therapy that cannot be discontinued. It should also be avoided in patients with known hypersensitivity to any component of the tablet.